Last reviewed · How we verify
NCT07062172
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
NA trial testing Low Dose CT Scan in Lung Cancer in 1,753 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | University of California, Irvine |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 1,753 |
| Start date | 8 May 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Low Dose CT Scan
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Driver Mutation — all drugs for Driver Mutation →
Sponsor
University of California, Irvine
Who can join
Adults 18 to 80, any sex, with Lung Cancer or Driver Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-armed screening research study which screens immediate family member of lung cancer patients with a driver mutation to see if lung cancer can be inherited and whether researchers can find lung cancer early. Immediate family members of lung cancer patients will be 40-80 years old and screened using a low dose CT scan.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07062172
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other University of California, Irvine trials
Trials by the same sponsor.
- NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction · NA · not yet recruiting
- NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound · Phase 4 · not yet recruiting
- NCT07527325 — Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma · Phase 2 · not yet recruiting
- NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room · NA · not yet recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07062172 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
- Last refreshed: 14 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07062172.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing